Broad immune and bladder tumor cell surface components

The term "Broad immune and bladder tumor cell surface components" does not refer to a single molecular target but rather describes the multifaceted interaction between Bacillus Calmette-Guérin (BCG) and the bladder microenvironment. BCG, a live attenuated strain of Mycobacterium bovis, is the standard intravesical immunotherapy for non-muscle invasive bladder cancer (NMIBC). Its efficacy depends on binding to the bladder wall through interactions with fibronectin and subsequent internalization by both normal urothelial cells and bladder cancer cells. This process initiates a complex immune cascade involving the secretion of cytokines and the recruitment of various effector cells, such as natural killer (NK) cells and cytotoxic T lymphocytes, which collectively mediate the destruction of tumor cells. Because BCG interacts with a wide array of cell surface molecules and triggers a broad immune response, it is characterized by this collective description rather than a specific protein receptor.

Other names

BCG targetsMycobacterium bovis BCG cell wall componentsBladder cancer immunotherapy targets

BCG therapy involves the attachment of live attenuated Mycobacterium bovis to the bladder wall via fibronectin, followed by internalization into urothelial and tumor cells, which triggers a robust local inflammatory response and recruitment of various immune cells (T cells, NK cells, macrophages) to eliminate tumor cells.